

Acute Liver Failure Meeting

December 4-5, 2006
Hyatt Regency Bethesda
Bethesda, MD

Agenda

Monday, December 4, 2006 – Cabinet and Judiciary Rooms (Meeting Level)

- 7:00 a.m. **Registration and Light Refreshments**
- 8:00 a.m. **Welcome and Aims**
Jay Hoofnagle, M.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),
National Institutes of Health (NIH)
- SESSION 1: EPIDEMIOLOGY AND ETIOLOGY OF ACUTE LIVER FAILURE (ALF)**
Moderators: *Jay Hoofnagle, M.D., and William Bernal, M.D.*
- 8:10 a.m. **ALF: Overview of the Problem**
William M. Lee, M.D.
University of Texas Southwestern Medical School
- 8:30 a.m. **ALF: Evaluation and Management**
Timothy Davern, M.D.
University of California at San Francisco
- 8:50 a.m. **Natural History of ALF**
Robert J. Fontana, M.D.
University of Michigan
- 9:10 a.m. **Epidemiology of ALF in Children**
Robert H. Squires, Jr., M.D.
Children's Hospital of Pittsburgh, University of Pittsburgh
- 9:30 a.m. Discussion
- 10:00 a.m. **Break**
- SESSION 2: LIVER TRANSPLANTATION (LT)**
Moderators: *Robert H. Squires, Jr., M.D., and Timothy Davern, M.D.*
- 10:30 a.m. **Issues in LT for ALF**
Lorenzo Rossaro, M.D.
University of California at Davis Medical Center
- 10:50 a.m. **Current Outcomes of LT for ALF**
Robert M. Merion, M.D.
University of Michigan
-

Monday, December 4, 2006 Continued – Cabinet and Judiciary Rooms

- 11:10 a.m. **Outcomes of Donors and Recipients Following Live Donor LT for ALF: A2ALL Study**
James Trotter, M.D.
University of Colorado Health Sciences Center
- 11:30 a.m. **LT for ALF in Children**
John Bucuvalas, M.D.
Cincinnati Children's Hospital
- 11:50 a.m. Discussion
- 12:20 p.m. **Lunch** (on your own)
- SESSION 3:** **ACETAMINOPHEN**
Moderators: *William M. Lee, M.D., and Andres T. Blej, M.D.*
- 1:20 p.m. **Updates on the Pathophysiology of Acetaminophen Hepatotoxicity**
Laura James, M.D.
University of Arkansas for Medical Sciences
- 1:40 p.m. **Intentional Versus Unintentional Overdoses**
Julie Polson, M.D.
University of Texas Southwestern Medical School
- 2:00 p.m. **Management of Acetaminophen Hepatotoxicity**
Anne Larson, M.D.
University of Washington
- 2:20 p.m. **Acetaminophen: UK Experience**
William Bernal, M.D.
Kings College Hospital, London, England
- 2:40 p.m. Discussion
- 3:10 p.m. **Break**
- SESSION 4:** **MEDICAL THERAPY OF ALF**
Moderators: *Edward Doo, M.D., and Anne Larson, M.D.*
- 3:40 p.m. **Autoimmunity and ALF: Can Autoimmune Hepatitis be Distinguished from Indeterminate Etiologies?**
R. Todd Stravitz, M.D.
Virginia Commonwealth University
- 4:00 p.m. **Viral Causes of ALF**
Anna S.F. Lok, M.D.
University of Michigan
- 4:20 p.m. **Prevalence, Demographics, and Outcome of ALF at the Medical University of South Carolina**
Adrian Reuben, M.D.
Medical University of South Carolina
-

Monday, December 4, 2006 Continued – Cabinet and Judiciary Rooms

- 4:40 p.m. **Metabolic Causes of ALF**
Ronald J. Sokol, M.D.
The Children's Hospital, Denver
- 5:00 p.m. Discussion
- 5:30 p.m. **POSTER SESSION** – Congressional Room
- 7:00 p.m. Adjourn for the Day

Tuesday, December 5, 2006 – Cabinet and Judiciary Rooms

- 7:00 a.m. **Light Refreshments**
- 8:00 a.m. **Welcome and Overview**
Organizers
- SESSION 5:** **NON-SPECIFIC THERAPIES FOR ALF**
Moderators: *Robert Fontana, M.D., and Anna S.F. Lok, M.D.*
- 8:10 a.m. **Hypothermia for ALF**
Andres T. Blej, M.D.
Northwestern University Feinberg School of Medicine
- 8:30 a.m. **N-Acetylcysteine for ALF**
William M. Lee, M.D.
University of Texas Southwestern Medical School
- 8:50 a.m. **Plasmapheresis for ALF**
Lars E. Schmidt, M.D., Ph.D.
Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
- 9:10 a.m. **Issues in Hepatic Assist Devices**
John "Jack" F. Patzer, II, Ph.D.
University of Pittsburgh, McGowan Institute for Regenerative Medicine
- 9:30 a.m. Discussion
- 10:00 a.m. **Break**
- SESSION 6:** **CELL FREE DEVICES**
Moderators: *Scott L. Nyberg, M.D., Ph.D., and Jörg C. Gerlach, M.D.*
- 10:30 a.m. **The Role of Extracorporeal Albumin Dialysis Using the Molecular Adsorbent Recirculating System in Patients with Liver Failure**
Tarek Hassanein, M.D.
University of California at San Diego Medical Center
-

Tuesday, December 5, 2006 Continued – Cabinet and Judiciary Rooms

- 10:50 a.m. **Plasma Filtration Therapy of ALF**
Jacek Rozga, M.D., Ph.D.
Arbios Systems, Inc.
- 11:10 a.m. **The Prometheus Filtration System**
Michael P. Manns, M.D.
Hanover Medical School, Hanover, Germany
- 11:30 a.m. Discussion
- 12:00 p.m. **Lunch** (on your own)
- SESSION 7: CELL-BASED DEVICES**
Moderators: *Jack Patzer, M.D., and William Lee, M.D.*
- 1:00 p.m. **Bioartificial Livers for ALF**
Scott L. Nyberg, M.D., Ph.D.
Mayo Clinic
- 1:20 p.m. **Three-Dimensional Perfusion Bioreactors for Human Progenitor
Expansion and Provision of Cells for Liver Cell Transplantation**
Jörg C. Gerlach, M.D.
University of Pittsburgh, McGowan Institute for Regenerative Medicine
- 1:40 p.m. **Potential of Stem Cells for Bioartificial Liver**
Lola M. Reid, Ph.D.
University of North Carolina at Chapel Hill School of Medicine
- 2:00 p.m. **Hepatocyte Transplantation for ALF**
Humberto E. Soriano, M.D.
St. Christopher's Hospital for Children and Drexel University College of Medicine
- 2:20 p.m. Discussion
- 2:50 p.m. **Break**
- SESSION 8: TISSUE ENGINEERING AND THE LIVER**
Moderators: *Christine A. Kelley, Ph.D., and Lola M. Reid, Ph.D.*
- 3:20 p.m. **Three-Dimensional Liver Models**
Linda C. Griffith, Ph.D.
Massachusetts Institute of Technology
- 3:40 p.m. **Synthetic Extracellular Matrices for 3-D Liver Regeneration**
Glenn D. Prestwich, Ph.D.
The University of Utah
- 4:00 p.m. **Liver Organ Engineering**
Geoffrey Gurtner, M.D.
Stanford University
- 4:20 p.m. Discussion
- 5:00 p.m. **Adjourn the Meeting**
-